To test the ADCC capacity of unmodified and engineered CD16Hi Vδ2 T cells, we performed in vitro tumor coculture assays with a preclinical anti-HER2 mAb analog to trastuzumab (Fig. 5a). Here, ERBB2 is linked to neoplasm.